Disease · MONDO_0022394
cervical intraepithelial neoplasia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. cervical intraepithelial neoplasia. Diseases, record MONDO_0022394. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0022394
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 5 of its 38 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs38
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| IMIQUIMOD | CHEMBL1282 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| BIZALIMOGENE RALAPLASMID | CHEMBL4297247 | Gene | Phase 3 | TTD | 3 | 2 | 2 | Drugs and targets |
| VERPASEP CALTESPEN | CHEMBL2108664 | Phase 3 | TTD | 3 | 2 | 1 | Drugs and targets | |
| ARUNDINE | CHEMBL446452 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FENRETINIDE | CHEMBL7301 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRICHLOROACETIC ACID | CHEMBL14053 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ARTESUNATE | CHEMBL361497 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HEXAMINOLEVULINATE | CHEMBL1201784 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | CHEMBL6068359 | Vaccine component | Phase 2 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
1 to 10 of 38
See all 38 drugsTargets26
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IFNAR1 | Interferon alpha/beta receptor | 3 | Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator | Phase 1 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 3 | Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator | Phase 1 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 2 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CHRNA4 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist | Unknown | https://conductscience.org/library/genes/1137 | Drugs and targets |
| CHRNB2 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist | Unknown | https://conductscience.org/library/genes/1141 | Drugs and targets |
| FDPS | Farnesyl pyrophosphate synthase | 1 | Farnesyl diphosphate synthase inhibitor | Phase 1 | https://conductscience.org/library/genes/2224 | Drugs and targets |
| PGR | Progesterone receptor | 1 | Progesterone receptor agonist | Phase 2 | https://conductscience.org/library/genes/5241 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor alpha | 1 | Peroxisome proliferator-activated receptor alpha agonist | Phase 1 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| PTGS2 | Prostaglandin G/H synthase 2 | 1 | Cyclooxygenase-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| TLR7 | Toll-like receptor 7 | 1 | Toll-like receptor 7 agonist | Phase 3 | https://conductscience.org/library/genes/51284 | Drugs and targets |
1 to 10 of 26
See all 26 targetsTrials45
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01256424 | Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia | Phase 2 | 262 | 2014-08-21 | Cervical Intraepithelial Neoplasia | HEXAMINOLEVULINATE | Its record names the disease | ClinicalTrials.gov |
| NCT02157610 | Smoking Cessation for Cervical Cancer Survivors | Not applicable | 202 | 2023-04-12 | Cervical Cancer, Tobacco Use, Smoking Cessation | (+/-)NICOTINE, NICOTINE | Its record names the disease | ClinicalTrials.gov |
| NCT02864147 | Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) | Phase 2 | 134 | 2024-05-02 | Cervical Intraepithelial Neoplasia, Cervical Dysplasia | IMIQUIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT00988559 | Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) | Phase 1 | 132 | 2018-07-09 | HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3) | IMIQUIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT00081263 | Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia | Phase 2 | 130 | 2017-09-15 | Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer | CELECOXIB | Its record names the disease | ClinicalTrials.gov |
| NCT00708942 | Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 | Phase 2 | 83 | 2013-04-15 | Cervical Intraepithelial Neoplasia | HEXAMINOLEVULINATE | Its record names the disease | ClinicalTrials.gov |
| NCT02354534 | Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) | Phase 1 | 30 | 2021-04-02 | Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain) | ARTESUNATE | Its record names the disease | ClinicalTrials.gov |
| NCT03196180 | Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia | Early phase 1 | 13 | 2022-02-23 | Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia | FLUOROURACIL, IMIQUIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT03267680 | IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 | Phase 2 | 10 | 2025-04-13 | Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion | CYCLOPHOSPHAMIDE, IRX-2 | Its record names the disease | ClinicalTrials.gov |
| NCT00462813 | Diindolylmethane in Treating Patients With Abnormal Cervical Cells | Phase 3 | 3,000 | Cervical Cancer, Precancerous Condition | ARUNDINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 45
See all 45 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Treatment (ST) vs Motivation + Problem Solving (MAPS): deaths from any cause | 4 of 100 | 4 of 102 | 202 | NCT02157610 | Trial comparisons |
| Arm I (Celecoxib) vs Arm II (Placebo): serious adverse events | 0 of 67 | 1 of 63 | 130 | NCT00081263 | Trial comparisons |
| Arm I (IRX-2) vs Arm II (Placebo): deaths from any cause | 0 of 7 | 0 of 3 | 10 | NCT03267680 | Trial comparisons |
| Arm I (IRX-2) vs Arm II (Placebo): serious adverse events | 0 of 7 | 0 of 3 | 10 | NCT03267680 | Trial comparisons |
Papers from its trials56
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0022394
GET https://conductscience.org/api/diseases/v1/MONDO_0022394/drugs?page=2